Epix tests MRI blood clot agent in phase II trial :
This article was originally published in Clinica
Epix Pharmaceuticals is starting a phase II proof-of-concept trial for its EP-2104R MRI-based agent for detecting blood clots throughout the body. The study's launch follows the completion late last year of a phase I trial that showed the agent to be well tolerated by healthy subjects at all doses tested. The phase II programme, which is expected to enrol around 40 patients, is being conducted at multiple clinical sites worldwide. Cambridge, Massachusetts-based Epix is collaborating on EP-2104R's development with German firm Schering.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.